Phase II Study of the Oral MEK Inhibitor Selumetinib in...

Clinical Cancer Research 2014 / 01 Vol. 20; Iss. 2

Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Jain, N., Curran, E., Iyengar, N. M., Diaz-Flores, E., Kunnavakkam, R., Popplewell, L., Kirschbaum, M. H., Karrison, T., Erba, H. P., Green, M., Poire, X., Koval, G., Shannon, K., Reddy, P. L., Joseph
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
20
Language:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-13-1311
Date:
January, 2014
File:
PDF, 462 KB
english, 2014
Conversion to is in progress
Conversion to is failed